Versant Capital Management Inc Has $115,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

Versant Capital Management Inc grew its position in Edwards Lifesciences Co. (NYSE:EW) by 102.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,553 shares of the medical research company’s stock after buying an additional 786 shares during the quarter. Versant Capital Management Inc’s holdings in Edwards Lifesciences were worth $115,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in EW. Lantz Financial LLC raised its stake in Edwards Lifesciences by 25.3% during the 2nd quarter. Lantz Financial LLC now owns 3,236 shares of the medical research company’s stock valued at $299,000 after purchasing an additional 654 shares during the period. Williams Financial LLC purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $201,000. TIAA Trust National Association lifted its holdings in shares of Edwards Lifesciences by 35.6% during the 2nd quarter. TIAA Trust National Association now owns 10,133 shares of the medical research company’s stock valued at $936,000 after buying an additional 2,662 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of Edwards Lifesciences by 6,016.7% in the 2nd quarter. Larson Financial Group LLC now owns 1,468 shares of the medical research company’s stock valued at $136,000 after buying an additional 1,444 shares in the last quarter. Finally, National Bank of Canada FI increased its holdings in Edwards Lifesciences by 17.0% in the second quarter. National Bank of Canada FI now owns 237,871 shares of the medical research company’s stock worth $21,452,000 after buying an additional 34,635 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EW has been the topic of several recent research reports. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Truist Financial reissued a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Stifel Nicolaus upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Robert W. Baird reduced their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Sixteen research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $79.40.

Edwards Lifesciences Stock Up 1.8 %

NYSE:EW opened at $73.91 on Friday. The stock has a 50-day simple moving average of $70.99 and a 200 day simple moving average of $72.83. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a market cap of $43.59 billion, a PE ratio of 10.67, a PEG ratio of 3.63 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the business earned $0.59 EPS. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,500 shares of company stock valued at $2,508,350 in the last three months. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.